Tolerance and Effect of a Prophylactical Treatment With Ivy Leaves Dry Extract in Recurrent Wheez… (NCT02045550) | Clinical Trial Compass
UnknownPhase 2
Tolerance and Effect of a Prophylactical Treatment With Ivy Leaves Dry Extract in Recurrent Wheezy Bronchitis
Germany60 participantsStarted 2014-01
Plain-language summary
To evaluate the effect of a prophylactical therapy with a cough medicine containing ivy leaves dry extract on the frequency of recurrent wheezy bronchitis in toddlers, on the duration of the bronchitis episodes, on the severity and the additional drug demand. A prolonged asymptomatic episode between each wheezy bronchitis due to the therapy is assumed.
Who can participate
Age range1 Year – 3 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Medical diagnosis of ≥3 episodes of wheezy bronchitis within the pre-vious 12 months
✓. Children aged from 1 to 3 years (girls and boys)
✓. Signed Informed Consent of the legal guardians to participate in the trial after written and verbal briefing by the Investigator
✓. No allergic sensitization
✓. Allowance to contact the familys pediatrician for medical history of wheezy bronchitis episodes
Exclusion criteria
✕. Anamnestically known intolerance/allergy to one of the drugs applied or to their ingredients or to drugs of similar chemical structure
✕. Participation of the patient in another clinical trial within the last four weeks before enrollment in this trial
✕. Evidence suggesting that the patient or their legal representative is not likely to follow the trial protocol (e.g. lacking compliance)
✕. Inability to document the symptoms in a symptom log book or ques-tionnaire; inability to take the trial medication properly
✕. Any regular therapy except Vitamin D or Fluoride
✕. Chronic illnesses of different aetiology
✕. Premature birth or diagnosis of bronchopulmonary dysplasia
What they're measuring
1
the time to event (next bronchitis episode) rate during and after treatment period